After a study where the activity of rivastigmine to decrease Aβ accumulation was showed, in 2016, Mohamed et al. [148] continued their work by crossing the transgenic AD mouse model APPSWE with mdr1a/b knockout mice to assess rivastigmine activity on three different levels of ABCB1 expression (APP+/mdr1+/+, APP+/mdr1+/−, and APP+/mdr1−/−). Here, APP is linked to Alzheimer disease.